The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitis
Abstract
Objective: To assess the clinical effects of rituximab therapy in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods: The study group comprised 11 patients who had active AAV despite receiving maximally tolerated doses of cyclophosphamide or had contraindications for cyclophosphamide use. All patients had ANCA reactive against proteinase 3. The patients received rituximab infusions and glucocorticoids to induce remission. Three patients also received plasma exchange. No other immunosuppressive agents were used. Glucocorticoids were tapered as soon as control of disease activity was achieved. Disease activity was monitored using the Birmingham Vasculitis Activity Score, modified for Wegener's granulomatosis. Results: Rituximab therapy was well tolerated by all patients, and adverse events were rare. Following the rituximab infusions, circulating B lymphocytes became undetectable, and ANCA titers decreased significantly. Remission was achieved in all patients and was maintained while B lymphocytes were absent. Conclusion: The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism‐based treatment modality for treatment of patients with these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Reinhold-Keller, E., Beuge, N., Latza, U., De Groot, K., Rudert, H., Nölle, B., Heller, M., & Gross, W. L. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1021::aid-anr10>3.0.co;2-j · Cited by 696
Boomsma, M. M., Stegeman, C. A., Van Der Leij, M. J., Oost, W., Hermans, J., Kallenberg, C. G. M., Limburg, P. C., & Tervaert, J. W. C. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<2025::aid-anr13>3.0.co;2-o · Cited by 434
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Differential B- and T-cell activation in Wegener’s granulomatosis
Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. M., & Tervaert, J. W. C. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70434-3 · Cited by 201
Suppression of human B lymphocyte function by cyclophosphamide.
Cupps, T. R., Edgar, L. C., & Fauci, A. S. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.6.2453 · Cited by 183
Pathways for self-tolerance and the treatment of autoimmune diseases
Goodnow, C. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05185-0 · Cited by 86
Current Attitudes to the Therapy of Vasculitis
Jayne, D. R. W. (2003) · Kidney & Blood Pressure Research · doi:10.1159/000072990 · Cited by 37
Leyendeckers, H., Schmitz, J., Tasanen, K., Bruckner‐Tuderman, L., Zillikens, D., Sitaru, C., & Hunzelmann, N. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12071.x · Cited by 34
Expression of host defense scavenger receptors in spondylarthropathy
McBeth (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200104)44:4 · Cited by 1
Cited by
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationRituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Self-citation
Metadata
- Authors
- Keogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-01
- Volume
- 52
- Issue
- 1
- Pages
- 262-268
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2057194530
- Cited by
- 450
- References
- 11
- FWCI
- 47.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.